CRNX · CIK 1658247
What Crinetics Pharmaceuticals, Inc. told the SEC could break it.
Crinetics' disclosures center on the concentrated channels and supply chain behind its newly launched lead drug, PALSONIFY. After the late-2025 U.S. launch, essentially all product revenue flows through just two customers — specialty distributors at 58% and 42% of gross product revenue — so losing either channel would disrupt nearly all sales. Its only commercial product also depends on a single, geographically fragmented manufacturing path, with paltusotine drug substance synthesized in India, optimized in Portugal and tableted in the U.S., where a disruption at any step would interrupt supply. That cross-border chain — plus raw materials imported from China — leaves it exposed to tariffs and export controls that could raise costs and impede imports.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- Two customers = 100% of gross product revenue (58% / 42%)high
Following PALSONIFY's Q4 2025 U.S. launch, essentially all of Crinetics' product revenue flows through just two customers (specialty distributors/pharmacies) — Customer A at 58% and Customer B at 42% of consolidated gross product revenue in 2025 — so loss of either channel relationship would disrupt nearly all product revenue.
“The following table summarizes customers that represented 10% or greater of our consolidated gross product revenue for the year ended December 31, 2025: Customer A 58 % Customer B 42 %”
SEC filing →As of 2026
Regulatory & policy
- Tariffs/export controls on imported API & materials (incl. China)medium
Tariffs, export controls and capital controls could raise the cost of manufacturing Crinetics' product candidates and platform materials and disrupt the import/export of raw materials and finished product — a direct concern given its India/Portugal/U.S. manufacturing chain and the raw materials it imports from China.
“export controls, capital controls or tariffs, may increase the cost of manufacturing our product candidates and platform materials, affect our ability to commercialize our product candidates if approved, the competitive position of our product candidates, and import or export of raw materials and finished product candidate used in our preclinical studies and clinical trials, particularly with respect to any product candidates and materials that we import from China.”
Supplier concentration
- Cross-border single-path API manufacturing — India → Portugal → U.S.medium
Crinetics' lead drug PALSONIFY depends on a single, geographically fragmented third-party manufacturing chain: paltusotine drug substance is synthesized in India, undergoes a bioavailability optimization step in Portugal, and is then tableted into finished drug product in the U.S. — so a disruption, trade barrier or capacity failure at any one of those single-location steps would interrupt its only commercial product.
“Currently, the drug substance for paltusotine is synthesized in India, undergoes a bioavailability optimization step in Portugal, and is then tableted into finished drug product in the U.S.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Sanwa Kagaku Kenkyusho Co., Ltd. (SKK)
“supplying certain materials to SKK for specified activities under the SKK License.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch